Co-Chairs
Santiago Rafael Bella, Argentina
Andrés Cervantes, Spain
Carlos Gil Moreira Ferreira, Brazil

Scientific Committee
Martin Ángel, Argentina
Santiago Rafael Bella, Argentina
Andrés Cervantes, Spain
Carlos Gil Moreira Ferreira, Brazil

Faculty
Laurence Albiges, France
Teresa Amaral, Germany
Emilio Batagelj, Argentina
Santiago Rafael Bella, Argentina
Virginia Bluthgen, Argentina
Valeria Caceres, Argentina
Andrés Cervantes, Spain
Matías Chacón, Argentina
Victoria Costanzo, Argentina
Giuseppe Curigliano, Italy
Mauricio Fernández Lazzaro, Argentina
Carlos Gil Moreira Ferreira, Brazil
Gonzalo Giornelli, Argentina
Gonzalo Gómez Abuin, Argentina
Guillermo Méndez, Argentina
Silvia Neciosup, Peru
Ana Oaknin, Spain
Juan Manuel O’Connor, Argentina
Solange Peters, Switzerland
Carmen Pupareli, Argentina
Daniela Rosa, Brazil
Juan Pablo Sade, Argentina
Manuela Schmiderger, Austria

Learning Objectives
• To provide the oncology community with a summary of the most significant treatment advances presented at the ESMO Congresses
• To review the current standard of care for key malignancies from a local and international perspective
• To discuss the current controversies in the management of specific cancers

Accreditation
The programme of this event has been accredited with 9 ESMO-MORA category-1 points.
Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further information please refer to www.esmo.org.
Friday, 28 April 2023

08:00-08:45 Summit Registration

Welcome & Introduction

09:00-09:10 Welcome address by AAOC President
Emilio Batagelj, AR

09:10-09:20 Welcome address by Summit Co-Chairs
Santiago Rafael Bella, AR
Andrés Cervantes, ES
Carlos Gil Moreira Ferreira, BR

09:20-09:30 Introduction by ESMO President
Andrés Cervantes, ES

Session 1 Cervical Cancer
Chair: Gonzalo Giornelli, AR

09:30-09:50 Current management of locally advanced cervical cancer
Valeria Caceres, AR

09:50-10:10 Current management of metastatic cervical cancer
Ana Oaknin, ES

10:10-10:30 Clinical case presentation
Ramiro Pedro Gonzalez, AR

10:30-11:00 Coffee break

Session 2 HER2-related Breast Cancer
Chair: Victoria Costanzo, AR

11:00-11:20 Current recommendations for HER2-amplified breast cancer
Giuseppe Curigliano, IT

11:20-11:40 Current recommendations for HER2-low breast cancer
Silvia Neciosup, PR

11:40-12:00 Management of toxicities of Antibody Drug Conjugates (ADC)
Daniela Rosa, BR

12:00-12:20 Clinical case presentation
Alexis Ostinelli, AR

12:20-13:20 Lunch break

Symposium Challenging clinical cases in HR+ HER2- Advanced Breast Cancer:
Discussion on how to choose the best treatment
Sponsored by Novartis Laboratory

12:20-13:00 Speakers: Pablo Mandó, AR, Alexis Ostinelli, AR and Belén Montenegro, AR

Note: Each 20-minute slot for clinical case presentation includes 10’ case presentation and 10’ Q&A / panel discussion
<table>
<thead>
<tr>
<th>Session 3</th>
<th>Triple Negative Breast Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair:</td>
<td>Victoria Costanzo, AR</td>
</tr>
<tr>
<td>13:20-13:40</td>
<td>How to treat localized Triple Negative Breast</td>
</tr>
<tr>
<td></td>
<td>Cancer in 2023 (peri-operative options)</td>
</tr>
<tr>
<td></td>
<td>Giuseppe Curigliano, IT</td>
</tr>
<tr>
<td>13:40-14:00</td>
<td>Main challenges in the treatment of Triple</td>
</tr>
<tr>
<td></td>
<td>Negative Breast Cancer in Latin America</td>
</tr>
<tr>
<td></td>
<td>Gonzalo Gómez Abuin, AR</td>
</tr>
<tr>
<td>14:00-14:20</td>
<td>Clinical case presentation</td>
</tr>
<tr>
<td></td>
<td>Federico Waisberg, AR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session 4</th>
<th>Non-Small-Cell Lung Cancer (NSCLC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair:</td>
<td>Virginia Blutghen, AR</td>
</tr>
<tr>
<td>14:20-14:40</td>
<td>Main challenges in the treatment of lung cancer</td>
</tr>
<tr>
<td></td>
<td>in Latin America</td>
</tr>
<tr>
<td></td>
<td>Carmen Pupareli, AR</td>
</tr>
<tr>
<td>14:40-15:00</td>
<td>Practice changing studies in lung cancer in</td>
</tr>
<tr>
<td></td>
<td>2023</td>
</tr>
<tr>
<td></td>
<td>Solange Peters, CH</td>
</tr>
<tr>
<td>15:00-15:20</td>
<td>Current recommendation for molecular subtyping</td>
</tr>
<tr>
<td></td>
<td>in NSCLC (tissue vs liquid samples)</td>
</tr>
<tr>
<td></td>
<td>Carlos Gil Moreira Ferreira, BR</td>
</tr>
<tr>
<td>15:20-15:40</td>
<td>Clinical case presentation</td>
</tr>
<tr>
<td></td>
<td>Andres Villa Labrín, CL</td>
</tr>
<tr>
<td>15:40-16:10</td>
<td>Coffee break</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Session 5</th>
<th>GU Cancers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair:</td>
<td>Mauricio Fernández Lazzaro, AR</td>
</tr>
<tr>
<td>16:10-16:30</td>
<td>Practice changing studies and current standards</td>
</tr>
<tr>
<td></td>
<td>of care in kidney cancer</td>
</tr>
<tr>
<td></td>
<td>Manuela Schmidinger, AT</td>
</tr>
<tr>
<td>16:30-16:50</td>
<td>Practice changing studies and current standards</td>
</tr>
<tr>
<td></td>
<td>of care in bladder cancer</td>
</tr>
<tr>
<td></td>
<td>Laurence Albiges, FR</td>
</tr>
<tr>
<td>16:50-17:10</td>
<td>Side effect management of tyrosine kinase</td>
</tr>
<tr>
<td></td>
<td>inhibitor therapy and immunotherapy combinations</td>
</tr>
<tr>
<td></td>
<td>Juan Pablo Sade, AR</td>
</tr>
<tr>
<td>17:10-17:30</td>
<td>Clinical case presentation</td>
</tr>
<tr>
<td></td>
<td>Matías Cerini, AR</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SELNET</th>
<th>Sarcoma European &amp; LatinAmerican NETwork</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair:</td>
<td>Matías Chacón, AR</td>
</tr>
<tr>
<td>17:30-17:45</td>
<td>Perspectives on neoadjuvant chemotherapy in</td>
</tr>
<tr>
<td></td>
<td>Soft Tissue Sarcomas</td>
</tr>
<tr>
<td></td>
<td>Javier Martín Broto, ES</td>
</tr>
<tr>
<td>17:45-17:50</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>

**Note:** Each 20-minute slot for clinical case presentation includes 10’ case presentation and 10’ Q&A / panel discussion.
Saturday, 29 April 2023

**Session 6**  
**Chair:** Matías Chacón, AR

- **09:00-09:20** Current management of locally advanced melanoma  
  Teresa Amaral, DE

- **09:20-09:40** Management of metastatic melanoma. How to treat in 2023  
  Matías Chacón, AR

- **09:40-10:00** Clinical case presentation  
  Ainur Okassova, AR

**10:00-10:40** Coffee break

**Symposium**  
**Impact of technology applied to treatment standards in Advanced Pancreatic Cancer**  
**Sponsored by Servier Laboratory**

- **Chair:** Lionel De la Roza, AR

- **10:40-10:45** Introduction  
  Lionel De la Roza, AR

- **10:45-11:00** Epidemiology and state-of-the-art in first line treatment  
  Marcela Carballido, AR

- **11:00-11:15** Treatment beyond first line  
  Romina Luca, AR

- **11:15-11:20** Q&A

**Session 7**  
**Chair:** Juan Manuel O’Connor, AR

- **11:20-11:40** Current recommendations for the treatment of advanced colorectal cancer  
  Andrés Cervantes, ES

- **11:40-12:00** Subtyping colorectal cancer for a precision treatment approach (HER2, BRAF...)  
  Guillermo Méndez, AR

- **12:00-12:20** Clinical case presentations  
  Luis Basbus, AR
  Romina Luca, AR

- **12:20-12:40** Closing remarks  
  Santiago Rafael Bella, AR
  Andrés Cervantes, ES
  Carlos Gil Moreira Ferreira, BR

**Note:** Each 20-minute slot for clinical case presentation includes 10’ case presentation and 10’ Q&A / panel discussion